keyword
MENU ▼
Read by QxMD icon Read
search

Surgery ovarian cancer

keyword
https://www.readbyqxmd.com/read/29685481/survival-of-selected-patients-with-ovarian-cancer-treated-with-fertility-sparing-surgery
#1
Nora Elisabeth Hedbäck, Mona Aarenstrup Karlsen, Claus Kim Høgdall, Mikkel Rosendahl
RESEARCH QUESTION: How many patients in Denmark were treated with fertility-sparing surgery (FSS) for epithelial ovarian cancer (EOC) and what was their prognosis compared with patients treated with radical surgery (RS)? DESIGN: This study was a retrospective Danish nationwide study, evaluating the effect of FSS compared with RS in patients with EOC, age ≤45 years and International Federation of Gynecology and Obstetrics (FIGO) stage ≤IC3 from 2005 to 2016. RESULTS: A total of 106 patients were included...
April 11, 2018: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/29683880/economic-analysis-of-neoadjuvant-chemotherapy-versus-primary-debulking-surgery-for-advanced-epithelial-ovarian-cancer-using-an-aggressive-surgical-paradigm
#2
Ashley L Cole, Emma L Barber, Anagha Gogate, Arthur-Quan Tran, Stephanie B Wheeler
OBJECTIVES: Neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) for advanced epithelial ovarian cancer (AEOC) remains controversial in the United States. Generalizability of existing trial results has been criticized because of less aggressive debulking procedures than commonly used in the United States. As a result, economic evaluations using input data from these trials may not accurately reflect costs and outcomes associated with more aggressive primary surgery. Using data from an ongoing trial performing aggressive debulking, we investigated the cost-effectiveness and cost-utility of NACT versus PDS for AEOC...
April 21, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29683235/a-study-of-clinicopathologic-factors-as-indicators-for-early-prediction-of-suboptimal-debulking-surgery-after-neoadjuvant-chemotherapy-in-advanced-ovarian-cancer
#3
Joo-Hyuk Son, Kyoungjin Chang, Tae-Wook Kong, Jiheum Paek, Suk-Joon Chang, Hee-Sug Ryu
AIM: This study aimed to evaluate early clinicopathologic factors predicting gross residual disease after neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer. METHODS: We analyzed clinicopathologic data of 68 patients with ovarian cancer who were treated with neoadjuvant chemotherapy followed by interval debulking surgery (NAC-IDS) between March 2006 and December 2016. All the patients received three cycles of NAC followed IDS. We evaluated all possible clinicopathologic characteristics, including reduction rates of serum CA-125 after each NAC and seven initial abdominopelvic computed tomography (CT) findings related to disease severity...
April 23, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29682189/cisplatin-liposome-and-6-amino-nicotinamide-combination-to-overcome-drug-resistance-in-ovarian-cancer-cells
#4
Daniela Catanzaro, Silvia Nicolosi, Veronica Cocetta, Marika Salvalaio, Andrea Pagetta, Eugenio Ragazzi, Monica Montopoli, Gianfranco Pasut
Ovarian cancer is an aggressive and lethal cancer usually treated by cytoreductive surgery followed by chemotherapy. Unfortunately, after an initial response, many patients relapse owing mainly to the development of resistance against the standard chemotherapy regime, carboplatin/paclitaxel, which is also affected by heavy side effects. In view to addressing such issues here, an association of liposomal cisplatin with 6-amino nicotinamide is investigated. It is known that resistant cells increase their demand for glucose, which is partially redirected toward the pentose phosphate pathway (PPP)...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29674421/anti-misrii-radiolabeled-antibodies-new-tools-for-a-theranostic-approach-in-ovarian-cancer
#5
Emmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, Alexandre Pichard, Catherine Lozza, Vincent Boudousq, Samuel Sevestre, Marta Jarlier, Roxana Kashani, Joanna Koch, Jane Sosabowski, Julie Foster, Nicolas Chouin, Frank Bruchertseifer, Alfred Morgenstern, Pierre-Olivier Kotzki, Isabelle Navarro-Teulon, Jean-Pierre Pouget
We have developed the 16F12 mouse monoclonal antibody (mAb) that targets the MISRII receptor expressed by ovarian tumors. Here, we assessed in preclinical models the possibility to use radiolabeled 16F12 in a theranostic approach for small-volume ovarian peritoneal carcinomatosis, for instance after cytoreductive surgery. Methods: DOTA-, DTPA- or DFO-conjugated 16F12 mAb was radiolabeled with beta (177 Lu) or alpha (213 Bi) particle emitters for therapeutic use, and with 89 Zr for positron emission tomography (PET) imaging...
April 19, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29670294/the-surgical-intelligent-knife-distinguishes-normal-borderline-and-malignant-gynaecological-tissues-using-rapid-evaporative-ionisation-mass-spectrometry-reims
#6
David L Phelps, Júlia Balog, Louise F Gildea, Zsolt Bodai, Adele Savage, Mona A El-Bahrawy, Abigail Vm Speller, Francesca Rosini, Hiromi Kudo, James S McKenzie, Robert Brown, Zoltán Takáts, Sadaf Ghaem-Maghami
BACKGROUND: Survival from ovarian cancer (OC) is improved with surgery, but surgery can be complex and tumour identification, especially for borderline ovarian tumours (BOT), is challenging. The Rapid Evaporative Ionisation Mass Spectrometric (REIMS) technique reports tissue histology in real-time by analysing aerosolised tissue during electrosurgical dissection. METHODS: Aerosol produced during diathermy of tissues was sampled with the REIMS interface. Histological diagnosis and mass spectra featuring complex lipid species populated a reference database on which principal component, linear discriminant and leave-one-patient-out cross-validation analyses were performed...
April 19, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29664847/ovarian-cancer-surgery-in-australia-and-new-zealand-a-survey-to-determine-changes-in-surgical-practice-over-10-years
#7
Rhonda Farrell, Winston Spencer Liauw, Alison Hilary Brand
OBJECTIVE: This study aimed to survey all practicing certified gynecological oncologists (CGOs) in Australia and New Zealand to determine their current surgical practice for primary advanced epithelial ovarian cancer (EOC) and compare the findings with an identical survey conducted 10 years previously. METHODS/MATERIALS: A questionnaire was e-mailed to all 53 practicing CGOs in Australia and New Zealand in July 2017 assessing their definition of optimal debulking for EOC, their use of neoadjuvant chemotherapy, and the surgical procedures they use to achieve cytoreduction...
April 16, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29658435/combined-immunotherapy-ok-432-il-2-with-chemotherapy-decrease-the-recurrence-rate-in-advanced-ovarian-cancer
#8
Yi-Lun Wang, Hsiu-Huei Peng, Sheng-Yuan Su, Cheng-Tao Lin
OBJECTIVE: In advanced ovarian cancer, traditional therapy included debulking surgery and postoperative chemotherapy. We proposed immunochemotherapy (IMCT) combined with picibanil (OK-432), interleukin-2 (IL-2), and traditional platinum- and taxol-based chemotherapy as a better treatment option for advanced ovarian cancer. METHODS: We retrospectively reviewed the medical records of 51 patients with advanced ovarian cancer between 2007 and 2015 at Chang Gung Memorial Hospital Linkou Medical Center, including 26 patients who were treated with OK-432, IL-2, and platinum- and taxol-based chemotherapy (IMCT group) after debulking surgery; another 25 were treated with traditional platinum- and taxol-based chemotherapy (traditional chemotherapy group) after debulking surgery...
January 1, 2018: Reproductive Sciences
https://www.readbyqxmd.com/read/29656331/survey-of-pelvic-reconstructive-surgeons-on-performance-of-opportunistic-salpingectomy-at-the-time-of-pelvic-organ-prolapse-repair
#9
Daisy B Hassani, Jeffrey M Mangel, Sangeeta T Mahajan, Adonis K Hijaz, Sherif El-Nashar, David Sheyn
INTRODUCTION AND HYPOTHESIS: Opportunistic salpingectomy (OS) at the time of benign hysterectomy has recently emerged as a potential primary preventive modality for ovarian cancer. Our objective was to determine whether the reported rate of OS at the time of prolapse surgery is similar to the rate of OS at the time of gynecologic surgery for non-prolapse indications. METHODS: An anonymous online survey was sent to the Society of Gynecologic Surgery members. Responses were divided into surgeons who did and did not perform OS at the time of prolapse repair...
April 14, 2018: International Urogynecology Journal
https://www.readbyqxmd.com/read/29656069/-microscopic-peritoneal-metastases-of-epithelial-ovarian-cancers-clinical-relevance-diagnostic-and-therapeutic-tools
#10
Y Kerbage, G Canlorbe, J P Estevez, A Grabarz, S Mordon, C Uzan, P Collinet, H Azaïs
Understanding the biology and progression mechanisms of peritoneal metastases in ovarian epithelial cancers (EOC) is important because peritoneal carcinomatosis is present or will occur during surveillance of a majority of patients. Despite the clinical remission achieved after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, 60% of patients will develop peritoneal recurrence. This suggests that microscopic lesions, which are not eradicated by surgery may be present and may participate in the mechanisms leading to peritoneal recurrence...
April 11, 2018: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/29651788/sphincter-preserving-surgery-for-recurrent-pelvic-malignancy-using-a-hybrid-procedure-of-open-laparotomy-and-transanal-endoscopic-approach
#11
Seiji Ishiguro, Shunichiro Komatsu, Kenichi Komaya, Takuya Saito, Takashi Arikawa, Kenichiro Kaneko, Tsuyoshi Sano
BACKGROUND: Surgery for the treatment of recurrent pelvic malignancy is challenging. Sphincter-preserving surgery (SPS) has been applied in limited cases. Transanal endoscopic approach (TEA) has been used for primary rectal cancer, predominantly for hybrid transabdominal-transanal total mesorectal excision. Here, we describe the use of TEA as a hybrid approach in a case of recurrent ovarian cancer. CASE PRESENTATION: A 59-year-old woman had recurrence of serous ovarian adenocarcinoma in the vaginal stump, near the site of anastomosis from a rectal resection 18 months previously...
April 12, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29627688/chemosensitizing-effects-of-metformin-on-cisplatin-and-paclitaxel-resistant-ovarian-cancer-cell-lines
#12
Isabella Dos Santos Guimarães, Taciane Ladislau-Magescky, Nayara Gusmão Tessarollo, Diandra Zipinotti Dos Santos, Etel Rodrigues Pereira Gimba, Cinthya Sternberg, Ian Victor Silva, Leticia Batista Azevedo Rangel
BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. Primary cytoreductive surgery with adjuvant taxane-platinum chemotherapy is the standard treatment to fight ovarian cancer, however, their side effects are severe, and chemoresistance emerges at high rates. Therefore, EOC clinic urges for novel treatment strategies to reverse chemoresistance and to improve the survival rates. Metformin has been shown to act in synergy with certain anti-cancer agents, overcoming chemoresistance in various types of tumors...
November 21, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29625193/icaritin-induces-ovarian-cancer-cell-apoptosis-through-activation-of-p53-and-inhibition-of-akt-mtor-pathway
#13
Lvfen Gao, Ming Chen, Yuan Ouyang, Ruobin Li, Xian Zhang, Xuesong Gao, Xiaoyu Wang, Shaoqiang Lin
AIMS: Ovarian cancer (OC) has the highest mortality rate of all gynecological cancers. Currently, the first-line OC treatment consists of cytoreductive surgery and platinum-based chemotherapy. However, most patients develop chemoresistance after the first-line treatment limits the success of treatment. Therefore, there is an urgent need to identify effective therapeutic agents. MAIN METHODS: Cell viabilities were detected by MTS assay; Annexin V-FITC/PI assay and western blotting assay were performed to analyze the apoptotic cells in vitro; An immunofluorescence assay was performed to analyze the TUNEL+ apoptotic cells in vivo; Patient-derived xenografts were established to test the in vivo antitumor effects; The key proteins of p53, caspase-mediated apoptotic pathway and Akt/mTOR pathway were detected by Western blotting...
April 3, 2018: Life Sciences
https://www.readbyqxmd.com/read/29624506/laparoscopic-assessment-to-determine-the-likelihood-of-achieving-optimal-cytoreduction-in-patients-undergoing-primary-debulking-surgery-for-ovarian-fallopian-tube-or-primary-peritoneal-cancer
#14
Vaagn Andikyan, Annie Kim, Herbert F Gretz, Konstantin Zakashansky, Monica Prasad-Hayes, Ann-Marie Beddoe, Peter Dottino, John Mandeli, Linus Chuang
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction (OC) in patients undergoing primary debulking surgery (PDS) for ovarian cancer. METHODS: All patients who underwent diagnostic laparoscopy and PDS at our institution from January 2008 to December 2013 were identified. We determined the likelihood of achieving optimal cytoreduction by laparoscopic assessment based on tumor site, pattern of spread, and disease burden...
April 5, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29623583/pathology-findings-and-clinical-outcomes-after-risk-reduction-salpingo-oophorectomy-in-brca-mutation-carriers-a-multicenter-spanish-study
#15
L Minig, S Cabrera, R Oliver, A Couso, M J Rubio, S Iacoponi, M B Martin-Salamanca, S Carballo-Rastrilla, J M Cádenas-Rebollo, A García-Garcia, B Gil-Ibáñez, M J Juan-Fita, M G Patrono
OBJECTIVE: To determine the incidence of serous tubal intraepithelial carcinoma (STIC) after risk reduction salpingo-oophorectomy(RRSO), and to describe oncological outcomes after RRSO. MATERIALS AND METHODS: BRCA pathogenic mutation carriers who had undergone an RRSO were evaluated in this retrospective multicenter observational study. Patients were only included when fallopian tubes were analyzed following the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM)...
April 5, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29623417/peri-operative-oral-immunonutrition-in-malnourished-ovarian-cancer-patients-assessed-by-the-nutritional-risk-screening
#16
Linda Hertlein, Christine Zeder-Göß, Sophie Fürst, Daniela Bayer, Fabian Trillsch, Bastian Czogalla, Sven Mahner, Alexander Burges, Peter Rittler
OBJECTIVES: Aim of this study was to determine whether peri-operative immunonutrition can decrease complications and the length of stay (LOS) in malnourished ovarian cancer patients. STUDY DESIGN: Patients suspicious for advanced ovarian cancer before histopathological diagnosis and a nutritional risk score (NRS) ≥ 3 received oral immune-modulating diets (IMDs) for 5 days pre-operative and at least 5 days post-operative. Parameters for clinical outcome were infectious and non-infectious complications during hospital stay, and time of hospitalization...
April 5, 2018: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29621126/examining-survival-outcomes-of-852-women-with-advanced-ovarian-cancer-a-multi-institutional-cohort-study
#17
Taymaa May, Alon Altman, Jacob McGee, Lin Lu, Wei Xu, Kelly Lane, Prafull Ghatage, Barry Rosen
INTRODUCTION: This study examines patterns of clinical practice in the management of women with advanced high-grade serous ovarian carcinoma (HGSC). METHODS: A total of 852 patients with advanced HGSC were included in this retrospective cohort analysis. Patients underwent primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy (NACT). Wilcoxon rank-sum test and χ test were applied. Univariate- and multivariate-analyses were performed, and survival outcomes were measured using Kaplan-Meier curves...
April 4, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29621040/concomitant-repair-of-pelvic-floor-disorders-in-women-undergoing-surgery-for-gynecologic-malignancies
#18
Katarzyna Bochenska, Margaret Mueller, Julia Geynisman-Tan, Alix Leader-Cramer, Bhumy Davé, Christina Lewicky-Gaupp, Kimberly Kenton
OBJECTIVE: The aims of this study were to determine the rate and describe 30-day postoperative complications of concomitant pelvic organ prolapse and/or urinary incontinence (POPUI) procedures in women undergoing surgery for a gynecologic malignancy. METHODS: Women who underwent surgical intervention for a gynecologic malignancy between 2010 and 2014 were identified using postoperative International Classification of Diseases, Ninth Revision codes 179.0 to 184.9 in the American College of Surgeons National Surgical Quality Improvement Program database...
April 4, 2018: Female Pelvic Medicine & Reconstructive Surgery
https://www.readbyqxmd.com/read/29620474/pharmacokinetic-drug-evaluation-of-niraparib-for-the-treatment-of-ovarian-cancer
#19
Teresa C Longoria, Krishnansu S Tewari
Ovarian cancer is a disease with a propensity to recur despite dramatic responses to initial treatment, which typically consists of a combination of cytoreductive surgery and platinum-based chemotherapy. A maintenance therapy, which may prevent or delay relapse while not negatively impacting quality of life, is critical to improving outcomes. Areas covered: This review discusses the pharmacologic properties, clinical efficacy, and safety profile of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy...
April 5, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29618939/-syk-expression-level-distinguishes-control-from-brca1-mutated-lymphocytes
#20
Tamar Zahavi, Amir Sonnenblick, Yael Shimshon, Luna Kadouri, Tamar Peretz, Asher Y Salmon, Mali Salmon-Divon
Background: About 5%-10% of breast cancer and 10%-15% of ovarian cancer are hereditary. BRCA1 and BRCA2 are the most common germline mutations found in both inherited breast and ovarian cancers. Once these mutations are identified and classified, a course of action to reduce the risk of developing either ovarian or breast cancer - including surveillance and surgery - is carried out. Purpose: The purpose of the current research is to characterize the gene expression differences between healthy cells harboring a mutation in BRCA1 /2 genes and normal cells...
2018: Cancer Management and Research
keyword
keyword
55599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"